Mandate

Vinge advises Orkla in connection with the acquisition of Zeelandia AB

Vinge has advised Orkla in connection with Orkla Food Ingredients AS’s acquisition of Zeelandia AB from Koninklijke Zeelandiaa Groep B.V.

Orkla is a leading actor of trademark and concept solutions for trading in convenience goods and large-scale catering institutions within the Nordic Region, Baltic Region, Central Europe and India. In 2018, the group’s turnover was NOK 41 billion and had approximately 18 500 employees. Orkla Food Ingredients is the largest actor within the bakery ingredients industry in the Nordic Region, and distributes products to 21 countries in total. The primary product categories are yeast, butter, plant‑based products, marzipan and margarine. Zeelandia AB’s product portfolio includes ingredients for all types of bread, buns, cakes and pastries as well as separating agents, balancing oils and food fillers, and is a strategic acquisition in order to strengthen Orkla’s position on the Nordic market. Following the acquisition, Zeelandia AB will change its name to Credin Sverige AB.

The acquisition is conditional upon the consent of the relevant competition authorities and other customary closing conditions.

Vinge’s team consisted of partners Peter Sundgren and Johan Karlsson together with, among others, associates Filip Öhrner, Christina Odengran, Isabelle Jengsell, Christoffer Nordin, Karin Virding, Lisa Ullman and project assistant Viktoria Owetz. Trine Osen Bergquist and Sebastian Örndahl provided competition law advice.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025